Table 5 Base case results: cost-effectiveness of testing ROS1 strategy vs. no-testing ROS1
Testing ROS1 | No-testing ROS1 | Difference | |
|---|---|---|---|
Cost of testing | € 2,843,608 | € 2,149,256 | € + 694,352 |
Cost of re-biopsy | € 72,543 | € 45,451 | € + 27,093 |
Cost of treatment | € 1,045,898,644 | € 1,044,375,352 | € + 1,523,292 |
Total costs | € 1,048,814,795 | € 1,046,570,058 | € + 2,244,737 |
PF-LYs | 10,288.15 | 10,218.90 | + 69.25 |
LYs | 23,226.07 | 23,068.58 | + 157.49 |
QALYs | 16,171.87 | 16,050.62 | + 121.25 |
ICER (€/LY gained) | € 14,254/LY | ||
ICUR (€/QALY gained) | € 18,514/QALY | ||